California Technology Biotech - Biomedical News

Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences: BioCentury Newsmakers in the Biotech Industry Thursday, September 4, 2008, 10:00 AM Eastern time Millennium Broadway Hotel, New York UBS...

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the Thomas Weisel Healthcare Conference in Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at the BioCentury NewsMakers Conference in New York on Thursday, September 4, 2008 at 11:30 a.m. ET, and at the Morgan Stanley Global Healthcare Unplugged Conference...

Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time)...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 4, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief...

Volcano Corporation (NASDAQ:VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Thomas Weisel Partners 2008 Healthcare Conference on...

Gen-Probe Incorporated (NASDAQ:GPRO) announced today that the Company will present at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at approximately 8 a.m. Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of...

Illumina, Inc. (NASDAQ:ILMN) today announced that the Company will webcast its presentations at two upcoming investment conferences in September 2008. Illumina will webcast its presentation at the Thomas Weisel Health Care Conference in Boston, Massachusetts on September 4, 2008. The live webcast is scheduled to begin at 3:50 p.m. ET....

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the Company is scheduled to present on Thursday, September 4, 2008, at 1:30 p.m. ET at the NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY. A live audio webcast of this presentation will be available on...

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The Thomas Weisel Partners 2008 Healthcare Conference on Thursday, September 4, 2008, at 2:40 p.m. Eastern Time...

Genoptix, Inc. (NASDAQ:GXDX), a specialized laboratory services provider, today announced the Company's participation at the 2008 Southern California Investor Conference scheduled to take place at The Islands Hotel in Newport Beach, CA on September 3, 2008. Sam Riccitelli, Executive Vice President and COO of Genoptix, will present at the conference on...

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA (exenatide) injection referencing pancreatitis. The companies were aware of the pancreatitis...

Cyntellect, a privately-held biotechnology company, and the Burnham Institute for Medical Research ( Burnham ) today announced they have entered into a joint collaboration to develop new applications on Cyntellect's in situ live cell imaging and laser processing product (called LEAP ) to accelerate research by Burnham's scientists. The collaboration efforts...

TorreyPines Therapeutics, Inc. (NASDAQ:TPTX) today announced that it received a deficiency notice from The NASDAQ Stock Market on August 21, 2008. The notice, in accordance with NASDAQ Marketplace Rule 4450(a)(5) Minimum Bid Price Requirement, states that the company's common stock has closed below $1.00 per share for 30 consecutive business days....

JMAR Technologies, Inc. (OTCBB: JMAR), a leading innovator in the development and commercialization of sensing systems for the detection of chemical, biological, radiological, nuclear and explosive (CBRNE) materials, today reported that The Johns Hopkins University Applied Physics Laboratory (APL) has awarded the Company a contract to develop two prototype special...

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the ER and PR image analysis applications available through its patented ScanScope slide scanning system. The FDA-cleared immunohistochemistry (IHC)...

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) will Web cast a conference call on Tuesday, August 26 at 5:00 p.m. ET/2:00 p.m. PT to discuss the recent FDA advisory on BYETTA (exenatide) injection. Leading the call for Amylin will be Daniel M. Bradbury, Amylin's President and...

Researchers at Scripps Translational Science Institute (STSI) have contributed to a major genetic breakthrough -- the discovery of a gene responsible for the majority of inherited cases of a common childhood cancer. The finding was reported online Aug. 24 in Nature. Neuroblastoma -- a cancer of the nervous system --...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Kevin Gorman, President and Chief Executive Officer will be presenting at both the Thomas Weisel Healthcare Conference in Boston and the NewsMakers in the Biotech Industry Conference in New York. The presentation at the Thomas Weisel Conference in Boston at the Four Seasons takes...

Invitrogen Corporation (NASDAQ:IVGN) today announced it has set the date for a special meeting of its shareholders, to consider the proposed acquisition of Applied Biosystems Inc. The special meeting of shareholders will be held on October 16, 2008, at 9 a.m., PT at Invitrogen’s headquarters, 5781 Van Allen Way, Carlsbad,...

Valeant Pharmaceuticals International (NYSE: VRX) today announced that members of its senior management team will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008 at 11:00 a.m. EDT. The conference will be held at The Grand Hyatt Hotel in New York, NY. A live...

The Moores UCSD Cancer Center today announced the 15th Annual Luau & Longboard Invitational will be held at The Scripps Institution of Oceanography on August 24, 2008 beginning at 7 a.m. The Luau & Longboard Invitational has established a unique international reputation for combining the aloha spirit of surfing with...

Ardea Biosciences, Inc. (NASDAQ:RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout. Regulatory clearance for us to proceed with...

Prometheus Laboratories Inc. announced the issuance of U.S. Patent No. 7,361,733, Compositions and Methods for the Therapy and Diagnosis of Inflammatory Bowel Disease which protects a flagellin peptide useful in the detection of antibodies to the flagellin Cbir1, or anti-CBir1, for determining the presence of inflammatory bowel disease (IBD)....

Vical Incorporated (NASDAQ:VICL) today announced that results from nonhuman primate studies of a Vaxfectin -formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising approach to the development of a measles vaccine to address an unmet need for human infants. Vical...

NovaRx Corporation announced today that the company initiated its pivotal Phase III clinical trial of Lucanix (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first patient enrolled in the study was treated by Dr. Lyudmila Bazhenova the trial's principal investigator at the University of California,...